Thank You!
Recently, thanks to all of our volunteers and staff, we have been able to contribute groundbreaking research in the fight against Alzheimer’s disease. We would like to thank all of you who have participated in any of our clinical trials, making this possible! Read more of the story below.
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
“Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer’s disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis,” said Anne White, executive vice president and president of Lilly Neuroscience, Eli Lilly and Company. “Our deepest thanks to the patients and their loved ones for participating in our clinical programs and to Lilly scientists and collaborators persevering over decades of research. Each year, more and more people are at risk for this disease, and we are determined to make life better for them.”
Alzheimer’s Association Welcomes U.S. FDA Approval of Kisunla (Donanemab)
“This is real progress. Today’s approval allows people more options and greater opportunity to have more time,” said Joanne Pike, DrPH, Alzheimer’s Association president and CEO. “Having multiple treatment options is the kind of advancement we’ve all been waiting for — all of us who have been touched, even blindsided, by this difficult and devastating disease.”
